ArticleFrontiers in radiology2026
Transcatheter arterial embolization using n-butyl cyanoacrylate metacryloxysulfolane for traumatic or iatrogenic non-visceral hemorrhage.
Article in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the safety and effectiveness of transcatheter arterial embolization (TAE) using n-butyl cyanoacrylate metacryloxysulfolane (NBCA-MS) as a first-line embolic agent for the management of traumatic and iatrogenic non-visceral arterial hemorrhages in an emergency setting. Materials and methods: This retrospective study included all consecutive patients who underwent selective TAE with NBCA-MS for non-visceral hemorrhage of traumatic or iatrogenic origin between June 2021 and June 2025. All patients were assessed with contrast-enhanced multidetector computed tomography (CT) demonstrating active arterial bleeding or pseudoaneurysm prior to embolization. TAE was performed via a femoral approach using selective microcatheterization, followed by embolization with NBCA-MS mixed with ethiodized oil at variable dilutions. Technical success was defined as complete angiographic occlusion of the bleeding vessels. Clinical success was defined as sustained hemostasis without need for repeat endovascular or surgical intervention /within 30 days. Procedure-related complications were recorded according to CIRSE guidelines. Results: Fifty-four patients (37 males; median age 60.5 years) underwent 54 TAE procedures. Traumatic hemorrhage accounted for 83.3% of cases, and iatrogenic hemorrhage for 16.7%. A single artery was embolized in 72.2% of procedures. Technical success was achieved in all cases (100%). Clinical success was observed in 46 patients (85.2%). Six patients required repeat embolization due to hemorrhage from vessels within the same vascular territory that had not been bleeding during the initial procedure and were therefore not embolized at that time. No procedure-related deaths, major complications, or off-target embolizations were observed. Conclusion: NBCA-MS-based TAE is a safe, effective, and versatile treatment for traumatic and iatrogenic non-visceral arterial hemorrhage. Its high technical success, favorable clinical outcomes, and excellent safety profile support its use as a reliable first-line embolic agent in urgent clinical scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.